Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

Crystalys Therapeutics has successfully closed an oversubscribed $130 million Series B financing round, aimed at advancing the late-stage global clinical development and commercialization of dotinurad, a next-generation treatment for gout. The financing was announced on July 22, 2026, and was led by Frazier Life Sciences, with significant participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, and KCap Biotechnology Fund, along with all existing investors.

Crystalys Therapeutics, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on addressing the unmet medical needs of patients suffering from gout. The company’s lead candidate, dotinurad, is a once-daily oral URAT1 inhibitor that aims to offer best-in-class safety and efficacy for gout treatment. Currently, gout is the most prevalent form of inflammatory arthritis, characterized by painful attacks due to excess uric acid in the body. Despite existing therapies, there remains a significant treatment gap, particularly for patients who do not respond adequately to first-line treatments.

The proceeds from this financing round will primarily support the ongoing clinical development of dotinurad, including two Phase 3 trials—RUBY and TOPAZ—as well as a Phase 2 study known as AMETHYST. These trials are designed to evaluate the efficacy of dotinurad across a diverse patient population, particularly those with limited treatment options. The funding will also facilitate commercialization preparation activities and provide operational runway as the company approaches critical clinical and regulatory milestones.

The biopharmaceutical sector, particularly in the treatment of chronic conditions like gout, is witnessing increased investment interest as companies strive to fill significant treatment gaps. Dotinurad's development highlights a broader trend towards innovative therapies that offer improved safety and efficacy profiles. With its regulatory approvals in markets such as Japan and China, Crystalys is well-positioned to leverage its clinical data and move towards commercialization in the U.S. and E.U., where there is a pressing need for effective second-line therapies.

As the biopharmaceutical landscape evolves, the successful fundraising by Crystalys Therapeutics underscores the growing confidence among investors in companies that are addressing unmet medical needs. The support from a diverse group of investors not only strengthens Crystalys’s financial position but also reflects the increasing recognition of the potential impact that innovative treatments like dotinurad can have on patient care. The outcome of the ongoing clinical trials will be pivotal in determining the future trajectory of both Crystalys Therapeutics and the broader gout treatment market.